Business
PAVmed Provides Business Update and Second Quarter 2024 Financial Results
Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX
About this update from Pavmed Inc.
[{"type":"text","content":"Lucid reports record quarterly EsoGuard® test volume and held productive meeting with CMS Medicare Administrative Contractor (MAC) Palmetto GBA's MolDX Program\nVeris Health actively pursuing financing following launch of pilot program with The Ohio State's James Cancer Hospital \nConference call and webcast to be held today, August 13th at 8:30 AM EDT\nNEW YORK, Aug. 13, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and presented financial results for the Company for the three months ended June 30, 2024.\n\n \n \n \n \n \n \n\n \nConference Call and Webcast\nThe webcast will take place on Tuesday, August 13, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.\nBusiness Update Highlights\n\"Our strategy for PAVmed remains to strengthen its finances and long-term stability by seeking to have each of its subsidiaries become independently financeable and well-positioned to leverage PAVmed's shared infrastructure,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. \"Lucid remains PAVmed's strongest asset and it has been able to independently finance its operations and continue to make solid progress over multiple fronts towards fulfilling its large commercial potential. PAVmed's two other subsidiaries, Veris Health and the PMX incubator are also advancing consistent with this strategy, with Veris and PMX asset PortIO actively pursuing independent financing.\nHighlights from the second quarter and recent weeks:\nLucid reported that 2Q24 EsoGuard® Esophageal DNA Test revenue was $1.0 million, which was flat ...